START Mountain Region

Running trials

• Not yet recruiting

  A Study of LY4336619 in Adult Participants With Advanced Solid Tumors

  NCT07928258· Phase 1· Source

• Recruiting

  Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

  NCT07745361· Phase 2· Source

• Recruiting

  A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer

  NCT07746713· Phase 1· Source

• Recruiting

  A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

  NCT07659795· Phase 2· Source

• Recruiting

  A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

  NCT07644559· Phase 2· Source

• Recruiting

  A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

  NCT07488676· Phase 1/2· Source

• Recruiting

  Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

  NCT07517198· Phase 1· Source

• Recruiting

  A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

  NCT07491497· Phase 1/2· Source

• Recruiting

  A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

  NCT07361562· Phase 1· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

  NCT07318805· Phase 1· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

  NCT07223047· Phase 1/2· Source

• Recruiting

  A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

  NCT07300150· Phase 1· Source

• Enrolling by invitation

  A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

  NCT07218003· Phase 1· Source

• Recruiting

  PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer

  NCT07190469· Phase 1· Source

• Recruiting

  Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

  NCT07145255· Phase 1/2· Source

• Recruiting

  Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

  NCT07030257· Phase 1/2· Source

• Recruiting

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· Phase 1/2· Source

• Recruiting

  A Study of LY4175408 in Participants With Advanced Cancer

  NCT07046923· Phase 1· Source

• Recruiting

  A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

  NCT06880549· Phase 1· Source

• Recruiting

  Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

  NCT06784193· Phase 1· Source

• Recruiting

  A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

  NCT06678659· Phase 1/2· Source

• Recruiting

  A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  NCT06465069· Phase 1· Source

• Recruiting

  FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  NCT06303505· Phase 1/2· Source

• Recruiting

  A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  NCT06400472· Phase 1· Source

• Recruiting

  A Phase 1/1b Study of IAM1363 in HER2 Cancers

  NCT06253871· Phase 1· Source

• Recruiting

  A Study of MGC026 in Participants With Advanced Solid Tumors

  NCT06242470· Phase 1· Source

• Active, not recruiting

  A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

  NCT06206837· Phase 1/2· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

  NCT06004245· Phase 1· Source

• Active, not recruiting

  A Study of ADRX-0706 in Select Advanced Solid Tumors

  NCT06036121· Phase 1· Source

• Recruiting

  A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  NCT06270706· Phase 1· Source

• Recruiting

  Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

  NCT05985655· Phase 1/2· Source

• Active, not recruiting

  Study of LP-184 in Patients With Advanced Solid Tumors

  NCT05933265· Phase 1/2· Source

• Active, not recruiting

  A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

  NCT05787587· Phase 1· Source

• Recruiting

  First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  NCT05768139· Phase 1/2· Source

• Recruiting

  Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

  NCT06132503· Phase 1· Source

• Recruiting

  Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  NCT05579366· Phase 1/2· Source

• Recruiting

  A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

  NCT05208762· Phase 1· Source

• Active, not recruiting

  CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

  NCT05251714· Phase 1/2· Source

• Active, not recruiting

  Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

  NCT04956640· Phase 1/2· Source

• Active, not recruiting

  A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

  NCT04577833· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer22 recruiting
• Colorectal cancer12 recruiting
• Ovarian cancer11 recruiting
• Pancreatic cancer11 recruiting
• Triple-negative breast cancer11 recruiting
• Gastric and esophageal cancer8 recruiting
• Prostate cancer7 recruiting
• Bladder cancer6 recruiting
• Cervical cancer6 recruiting
• Endometrial cancer6 recruiting
• Head and neck cancer6 recruiting
• Liver and biliary tract cancer5 recruiting
• Melanoma4 recruiting
• Kidney cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Sarcoma3 recruiting
• Childhood cancers1 recruiting
• Mesothelioma1 recruiting
• Neuroendocrine tumours1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

  NCT06546553· Phase 1· Source

• Terminated

  A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

  NCT06364696· Phase 1· Source

• Terminated

  A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

  NCT06264921· Phase 1· Source

• Recruiting

  A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

  NCT06244771· Phase 1/2· Source

• Completed

  A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT05848011· Phase 2· Source

• Completed

  A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

  NCT05864144· Phase 1/2· Source

• Terminated

  A Study of SGN-ALPV in Advanced Solid Tumors

  NCT05229900· Phase 1· Source

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Phase 1/2· Source

• Terminated

  Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

  NCT03809624· Phase 1· Source